Protagonist Therapeutics, Inc.
PTGX
Rank in Stocks
#2280
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Share Price
$136.61
Market Cap
$8.84B
Change (1 day)
1.61%
Change (1 year)
78.06%
Country
US
Trade Protagonist Therapeutics, Inc. (PTGX)
Category
Healthcare
Number of shares outstanding for Protagonist Therapeutics, Inc. (PTGX)
Number of shares outstanding as of June 2026: 65.94M
According to Protagonist Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 65.94M. At the end of December 2023 the company had 56.76M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Protagonist Therapeutics, Inc. (PTGX) from 2014 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 65.94M | 7.10% |
| 2024 | 61.57M | 8.46% |
| 2023 | 56.76M | 15.74% |
| 2022 | 49.04M | 5.87% |
| 2021 | 46.32M | 34.67% |
| 2020 | 34.40M | 32.84% |
| 2019 | 25.89M | 15.78% |
| 2018 | 22.36M | 26.39% |
| 2017 | 17.69M | 172.15% |
| 2016 | 6.50M | 10.48% |
| 2015 | 5.88M | 0.00% |
| 2014 | 5.88M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 285.07% |
US
|
|
| 396.00M | 500.58% |
US
|
|
| 478.91M | 626.33% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -5.69% |
NL
|
